EcoDrugPlus

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSVVUG00000015291
Gene Symbol: LCK
2 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSVVUG00000017823
Gene Symbol: LYN
3 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSVVUG00000015734
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSVVUG00000000900
Gene Symbol: MAPKAPK2
3 Cross references
233 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSVVUG00000013166
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSVVUG00000007048
Gene Symbol: MKNK1
3 Cross references
167 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSVVUG00000002443
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSVVUG00000011532
Gene Symbol: MCL1
3 Cross references
239 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSVVUG00000010494
Gene Symbol: MET
3 Cross references
176 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSVVUG00000008486
Gene Symbol: MPL
3 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSVVUG00000009311
Gene Symbol: MLST8
3 Cross references
201 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSVVUG00000018823
Gene Symbol: NOX4
3 Cross references
151 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).